Cargando…
Targeting the adaptive molecular landscape of castration-resistant prostate cancer
Castration and androgen receptor (AR) pathway inhibitors induce profound and sustained responses in advanced prostate cancer. However, the inevitable recurrence is associated with reactivation of the AR and progression to a more aggressive phenotype termed castration-resistant prostate cancer (CRPC)...
Autores principales: | Wyatt, Alexander W, Gleave, Martin E |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Ltd
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4520654/ https://www.ncbi.nlm.nih.gov/pubmed/25896606 http://dx.doi.org/10.15252/emmm.201303701 |
Ejemplares similares
-
Novel non-AR therapeutic targets in castrate resistant prostate cancer
por: Toren, Paul J., et al.
Publicado: (2013) -
Targeting molecular resistance in castration-resistant prostate cancer
por: Chandrasekar, Thenappan, et al.
Publicado: (2015) -
Dissecting the Hormonal Signaling Landscape in Castration-Resistant Prostate Cancer
por: Fontana, Fabrizio, et al.
Publicado: (2021) -
The Current Landscape of Treatment in Non-Metastatic Castration-Resistant Prostate Cancer
por: El-Amm, Joelle, et al.
Publicado: (2019) -
Clinical Actionability of the Genomic Landscape of Metastatic Castration Resistant Prostate Cancer
por: Devlies, Wout, et al.
Publicado: (2020)